2023
Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures
Hsu J, Darden D, Du C, Marine J, Nichols S, Marcus G, Natale A, Noseworthy P, Selzman K, Varosy P, Masoudi F, Freeman J, Curtis J, Akar J, Kowey P. Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures. Journal Of The American College Of Cardiology 2023, 81: 867-878. PMID: 36858707, DOI: 10.1016/j.jacc.2022.11.060.Peer-Reviewed Original ResearchConceptsAtrial fibrillation ablation proceduresAblation RegistryHospital outcomesAblation proceduresSuccessful pulmonary vein isolationNational Cardiovascular Data RegistryOutcomes of patientsProspective cohort studyMajority of patientsPulmonary vein isolationEvidence-based guidelinesDifferent patient outcomesReal-world prevalenceProcedural admissionsHospital deathAF ablationCohort studyPericardial effusionVein isolationHeart failureLarge multicenterMajor complicationsCatheter ablationTreatment patternsPatient population
2021
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyAtrial fibrillation/flutterChronic lung diseaseCardiac sarcoidosisHeart failureCS patientsNICM patientsICD implantationLung diseaseNew York Heart Association class III heart failureNational Cardiovascular Data Registry ICD RegistryNYHA class IV heart failureClass III heart failureClass IV heart failureImplantable cardioverter defibrillator implantationKaplan-Meier survival curvesCox proportional hazards modelPredictors of mortalityCardioverter-defibrillator implantationVentricular ejection fractionMultivariable logistic regressionPrior ventricular arrhythmiasProportional hazards modelRate of deathTime of implantationNational Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure
Reinhardt SW, Chouairi F, Miller PE, Clark KAA, Kay B, Fuery M, Guha A, Freeman JV, Ahmad T, Desai NR, Friedman DJ. National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal Of The American Heart Association 2021, 10: e019412. PMID: 34013736, PMCID: PMC8483517, DOI: 10.1161/jaha.120.019412.Peer-Reviewed Original ResearchConceptsReduced ejection fractionComorbid atrial fibrillationHeart failureAtrial fibrillationEjection fractionHospital mortalityHF hospitalizationBackground Heart failureConclusion Atrial fibrillationWhite individualsNational Inpatient SampleMedian hospital chargesMore comorbiditiesComorbid hypertensionHF admissionsHF outcomesPatient demographicsDiabetes mellitusHospital admissionHospital chargesInpatient SampleVascular diseaseHospitalizationPatientsMortalityEffects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial
2020
Mortality and readmission in non-ischemic compared with ischemic cardiomyopathies after implantable cardioverter-defibrillator implantation
Freeman J, Bjerre J, Parzynski C, Minges K, Ahmad T, Desai N, Enriquez A, Spatz E, Friedman D, Curtis J, Hlatky M, Higgins A. Mortality and readmission in non-ischemic compared with ischemic cardiomyopathies after implantable cardioverter-defibrillator implantation. European Heart Journal 2020, 41: ehaa946.0788. DOI: 10.1093/ehjci/ehaa946.0788.Peer-Reviewed Original ResearchNon-ischemic cardiomyopathyImplantable cardioverter defibrillator implantationPrimary prevention ICDsCardioverter-defibrillator implantationIschemic cardiomyopathyICM patientsNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression modelPrimary prevention ICD implantationLeft ventricular ejection fractionProportional hazards regression modelsOne-year mortalityHeart failure readmissionVentricular ejection fractionKaplan-Meier curvesHazards regression modelsRisk of mortalityMedian followCause readmissionICD implantationEjection fractionHeart failureHospital readmissionICD RegistryPatient subgroupsComparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation
Higgins AY, Bjerre J, Parzynski CS, Minges KE, Ahmad T, Desai NR, Enriquez A, Spatz ES, Friedman DJ, Curtis JP, Hlatky MA, Freeman JV. Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation. The American Journal Of Cardiology 2020, 133: 116-125. PMID: 32862971, DOI: 10.1016/j.amjcard.2020.07.035.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyImplantable cardioverter defibrillator implantationCardioverter-defibrillator implantationICM patientsIschemic cardiomyopathyNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression modelPrimary prevention ICD implantationLeft ventricular ejection fractionProportional hazards regression modelsPrimary prevention ICDsRetrospective cohort studyVentricular ejection fractionKaplan-Meier curvesHazards regression modelsRisk of mortalityComparison of mortalityMedian followCohort studyICD implantationEjection fractionHeart failureHospital readmissionICD RegistryPatient subgroups
2019
Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications
Freeman JV, Tabada GH, Reynolds K, Sung SH, Singer DE, Wang PJ, Liu TI, Gupta N, Hlatky MA, Go AS. Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. The American Journal Of Cardiology 2019, 125: 553-561. PMID: 31843233, PMCID: PMC6987016, DOI: 10.1016/j.amjcard.2019.11.004.Peer-Reviewed Original ResearchConceptsTransient ischemic attackChronic antiarrhythmic therapyHeart failure hospitalizationIschemic attackAntiarrhythmic therapyAF ablationIschemic strokeIntracranial hemorrhageAntiarrhythmic medicationsFailure hospitalizationCatheter ablationAdverse outcomesAdjusted ratesKaiser Permanente Northern CaliforniaLong-term adverse outcomesAtrial fibrillation catheter ablationAF catheter ablationHigh-dimensional propensity scoreHistory of diabetesHistory of hypertensionCoronary heart diseaseHealthcare delivery systemCause hospitalizationObservational cohortHeart failureGuideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
Loring Z, Shrader P, Allen LA, Blanco R, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Mahaffey KW, Naccarelli GV, Pieper K, Reiffel JA, Singer DE, Steinberg BA, Thomas LE, Peterson ED, Piccini JP. Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal 2019, 219: 21-30. PMID: 31710841, PMCID: PMC7285625, DOI: 10.1016/j.ahj.2019.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCardiovascular DiseasesCause of DeathComorbidityCoronary Artery DiseaseDiabetes MellitusDisease ProgressionEmbolismFemaleGuideline AdherenceHeart FailureHumansHyperlipidemiasHypertensionIntracranial EmbolismMalePeripheral Nervous System DiseasesPeripheral Vascular DiseasesRegistriesSleep Apnea, ObstructiveTreatment OutcomeConceptsGuideline-directed therapyAtrial fibrillationCause mortalityHeart failureAF progressionLower riskNew-onset heart failureObstructive sleep apnea patientsCox proportional hazards modelBetter Informed TreatmentObstructive sleep apneaSleep apnea patientsProportional hazards modelAF patientsDiabetes mellitusNeurovascular eventsClinical outcomesOutcomes RegistrySleep apneaApnea patientsComorbiditiesHazards modelNonsignificant trendPatientsLower mortality
2018
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationComorbidityFemaleHealth StatusHeart Conduction SystemHemorrhageHospitalizationHumansLungMalePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAtrial fibrillationSymptom burdenHeart failurePulmonary diseaseHigh riskDiagnosis of COPDNew-onset heart failureTreatment of AFBeta-blocker useCardiovascular risk factorsMajor bleeding eventsHigh symptom burdenBetter Informed TreatmentCoronary artery diseaseOutcomes of adultsQuality of lifeBleeding eventsDigoxin useBlocker useCause mortalityProspective registryReversible causesCardiovascular mortality
2015
Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High‐risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY‐AF)
Turakhia MP, Ullal AJ, Hoang DD, Than CT, Miller JD, Friday KJ, Perez MV, Freeman JV, Wang PJ, Heidenreich PA. Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High‐risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (STUDY‐AF). Clinical Cardiology 2015, 38: 285-292. PMID: 25873476, PMCID: PMC4654330, DOI: 10.1002/clc.22387.Peer-Reviewed Original ResearchConceptsAT/AFSilent atrial fibrillationSupraventricular ectopic complexesAtrial fibrillationAtrial tachycardiaEctopic complexesRisk factorsContinuous ambulatory electrocardiographic monitoringDevelopment of AFPrior atrial fibrillationTransient ischemic attackAsymptomatic atrial fibrillationHigh-risk patientsProspective screening studyAmbulatory electrocardiographic monitoringUndiagnosed atrial fibrillationContinuous ambulatory ECG monitoringCombined diagnostic yieldScreening studyAmbulatory electrocardiogram monitoringAmbulatory ECG monitoringIschemic attackCoronary diseaseHeart failureElectrocardiographic monitoring
2014
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaChi-Square DistributionDigoxinFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedPatient SelectionPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeConceptsRisk of deathIncident atrial fibrillationAtrial fibrillationDigoxin useHigh riskHeart failureIndependent associationPropensity score-matched adultsKaiser Permanente NorthernPrevious heart failureRetrospective cohort studyResearch Network StudySubgroups of ageCohort studyCox regressionAdverse outcomesRisk factorsHospitalizationFibrillationDigoxinDeathLimited dataAdultsRiskHigh rate
2013
Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and Safety of Digoxin Among Contemporary Adults With Incident Systolic Heart Failure. Circulation Cardiovascular Quality And Outcomes 2013, 6: 525-533. PMID: 24021697, DOI: 10.1161/circoutcomes.111.000079.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCaliforniaCardiotonic AgentsChi-Square DistributionDigoxinDisease ProgressionDrug Therapy, CombinationFemaleGuideline AdherenceHealth Maintenance OrganizationsHeart Failure, SystolicHospitalizationHumansIncidenceMaleMiddle AgedMultivariate AnalysisPractice Guidelines as TopicProportional Hazards ModelsRisk FactorsSex FactorsTime FactorsTreatment OutcomeConceptsIncident systolic heart failureSystolic heart failureSafety of digoxinΒ-blocker useDigoxin useHeart failureHF hospitalizationConcurrent β-blocker useSymptomatic systolic heart failureKaiser Permanente Northern CaliforniaHF disease severityOptimal medical therapyRisk of deathMedical therapyMultivariable analysisContemporary cohortCox regressionClinical guidelinesMedical historyHigh riskHospitalizationHigh mortalityPatientsDisease severityTrial dataUse of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation
Hess PL, Kim S, Piccini JP, Allen LA, Ansell JE, Chang P, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Fonarow GC. Use of Evidence-based Cardiac Prevention Therapy Among Outpatients with Atrial Fibrillation. The American Journal Of Medicine 2013, 126: 625-632.e1. PMID: 23787195, PMCID: PMC4037289, DOI: 10.1016/j.amjmed.2013.01.037.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntihypertensive AgentsAtrial FibrillationCardiovascular DiseasesComorbidityDefibrillators, ImplantableEvidence-Based PracticeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLogistic ModelsMalePlatelet Aggregation InhibitorsPractice Guidelines as TopicRegistriesRisk FactorsConceptsCardiovascular comorbid conditionsEvidence-based therapiesAtrial fibrillationRisk factorsComorbid conditionsEvidence-based therapy useMore evidence-based therapiesGuideline-recommended therapiesAngiotensin receptor blockersAntiarrhythmic drug therapyCardiovascular risk factorsPeripheral vascular diseaseMinority of patientsCoronary artery diseaseMultivariable logistic regressionUS national registryAngiotensin-converting enzymeAldosterone antagonistsComorbid illnessesReceptor blockersComorbid diseasesAntiplatelet agentsArtery diseaseDiabetes mellitusHeart failureEffectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease
Chang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β-Blockers in Heart Failure With Left Ventricular Systolic Dysfunction and Chronic Kidney Disease. Journal Of Cardiac Failure 2013, 19: 176-182. PMID: 23482078, PMCID: PMC4126798, DOI: 10.1016/j.cardfail.2013.01.006.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseVentricular systolic dysfunctionΒ-blocker therapyHeart failure hospitalizationIncident heart failureHeart failureKidney diseaseSystolic dysfunctionFailure hospitalizationΒ-blockersLower riskKaiser Permanente Northern California systemLeft ventricular systolic dysfunctionLower crude riskCombined end pointΒ-blocker useGlomerular filtration rateAssociation of treatmentMultivariable adjustmentCrude riskMedication effectivenessCox regressionPotential confoundersFiltration rateMethodologic limitations